Gene Expression Signatures Predict Immunotherapy Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapies for cancer lack predictive biomarkers to identify which patients will respond effectively, leading to variable treatment outcomes and inefficiencies in personalized medicine.
Innovation Solution
The use of elevated expression levels of specific genes (ABCA1, TMEM245, ATP13A3, and OLR1) as molecular signatures to predict patient response to immunotherapies, particularly immune checkpoint immunotherapies, allowing for the identification of subjects likely to benefit from these treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If immunotherapies are administered to cancer patients, then treatment coverage is improved, but treatment effectiveness varies significantly because predictive biomarkers are lacking
Solution Approach 1:
The patent applies preliminary action by determining gene expression levels (ABCA1, TMEM245, ATP13A3, OLR1) before administering immunotherapy to identify patients likely to respond. This pre-screening approach allows clinicians to predict treatment outcomes in advance, ensuring that immunotherapy is directed toward patients with elevated expression of these genes, thereby improving both treatment coverage and effectiveness.
2Ease of operation
If molecular signatures are used to predict immunotherapy response, then personalized treatment is improved, but measurement complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the complex task of predicting immunotherapy response into measurement of specific, discrete gene expression levels (ABCA1, TMEM245, ATP13A3, OLR1). Rather than analyzing the entire genome, the invention focuses on this specific subset of genes, making the measurement process more manageable and clinically feasible while still providing accurate personalized treatment predictions.
Data Source
Figure 1
Figure 2
AI summary
The present invention relates to methods relating to the prediction of the response of a subject to immunotherapies, preferably immune checkpoint inhibitors, wherein said methods are based on the determination of the expression levels of a set of genes, and subsequent comparison with control values. Furthermore, the invention also relates to a kit comprising means for determining the expression levels of said genes.